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GIP is a 42 amino acid peptide 
(Drucker, 2006, p. 153) secreted from 
duodenum K-cells in the proximal small 
intestine and is transported through the 
blood (Pratley, n.d., p. 7).  Nutrient 
intake stimulates GIP production; GIP 
levels are low in the fasted state and will 
rise within minutes of food consumption 
(Drucker, 2006).  GIP has direct effects 
on insulin secretion that are mediated 
through a specific receptor for GIP on β 
cells (Pratley, n.d., p. 8).  GIP has a short 
half-life of seven minutes (Cornell, 
2013), and is eliminated from the 
circulation via the kidneys (Drucker, 
2006).  GIP is rapidly inactivated by 
dipeptidyl peptidase-4 (DPP-4), an 
exopeptidase (Drucker, 2013). 
According to Drucker (2006), GIP does 
not appear to be important for control of 
fasting glucose. 
The nurse practitioner (NP), often 
serving as the primary care provider has 
many options in treating the patient with 
T2DM. Treatment related side effects 
such as weight gain and hypoglycemia 
are usually a concern to the patient, 
which could deter the patient from 
following the treatment regimen 
prescribed (Bartol, 2012).  Selecting 
treatments that minimize side effects can 
help patients feel more optimistic and 
motivate them to continue taking their 
medications (Bartol, 2012). Prior to 
starting an incretin-based drug therapy 
the NP should obtain an A1C and 
according to Bartol (2012), one month 
after initiation of incretin therapy to see 
if the incretin analog is lowering glucose 
levels.  At the one month follow-up visit 
if the A1C is not improving, consider a 
change in the treatment regimen, and 
assess for nausea and weight loss at this 
follow-up visit (Bartol, 2012). 
The incretin therapies are an 
established component of diabetes 
management and the NP can be a key 
player in educating and prescribing 
medications; NPs play an essential role in 
motivating their patients to become 
active participants in their diabetes 
management. Motivating and 
encouraging lifestyle changes will help 
the patient to achieve improved diabetes 
control (Bartol, 2012).   
 
Type 2 diabetes mellitus (T2DM) is a 
progressive disease characterized as 
having pancreatic β-cell dysfunction, 
insulin resistance and hyperglycemia 
(Stephens, 2010, p. 491).  T2DM affected 
29.1 million Americans or 9.3% of the 
population in 2012 and was the seventh 
leading cause of death in the United 
States in 2010 ("ADA Statistics," 2014), 
with many of these patients finding it 
difficult to achieve or maintain adequate 
glycemic control despite making lifestyle 
changes and pharmacologic interventions 
(Freeman, 2007).  
Disease management of T2DM 
requires a comprehensive plan including 
medication therapy, education and active 
involvement of the patient, with the goal 
of therapy to lower the A1C (Robertson, 
2012).  Incretin mimetics are a class of 
medications available for treating 
patients with T2DM; they mimic the 
action of incretin hormones released 
during nutrient absorption (Freeman, 
2007).  Patients with T2DM have an 
impaired incretin response (Pratley, n.d., 
p. 8).  
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GLP-1 receptor agonists are long-
acting which make them resistant to GLP-
1 inactivation by DPP-4 (Stephens, 
2010). According to Capaldi (2012), self-
monitoring of blood glucose is not 
needed to adjust the dose of the agent 
prescribed since GLP-1 action is glucose-
dependent.   
GLP-1 receptor agonists should be 
avoided in patients with gastroparesis, 
and patients need educated that nausea 
is most often transient, and they should 
be counseled to eat smaller meals 
(Williams & Prasad-Reddy, 2012, p. 371). 
Hypersensitivity reactions exist for DPP-
4 inhibitors: anaphylaxis, angioedema, 
exfoliative skin conditions, and bronchial 
hyperreactivity.  Angioedema was the 
most commonly reported 
hypersensitivity reactions of the DPP-4 
inhibitors (Williams & Prasad-Reddy, 
2012, p. 371). DPP-4 inhibitor-induced 
angioedema is related to reduced DPP-4 
enzymatic activity and inhibited 
degradation of proinflammatory 
bradykinins and substance P (Williams & 
Prasad-Reddy, 2012, p. 371). Pancreatitis 
is listed as a precaution for GLP-1 
agonists and DPP-4 inhibitors (Williams 
& Prasad-Reddy, 2012). GLP-1 agonists 
may prove to have a cardioprotective 
function that is both receptor-dependent 
and receptor-independent.  Binding of 
the GLP-1 receptor in the myocardium 
stimulates an increase of inotropic action 
(Williams & Prasad-Reddy, 2012, p. 372).  
 
Incretin Effect 
The incretin effect is the secretion of 
insulin after ingestion of food compared 
to the isoglycemic intravenous glucose 
challenges (Ahren, 2013). Incretins are 
peptide hormones that originate in the 
gut and increase the effectiveness of 
insulin secretion after meal ingestion in a 
glucose-dependent manner (Campbell & 
Drucker, 2013). Glucose-dependent 
insulinotropic polypeptide (GIP) and 
glucagon-like-peptide-1 (GLP-1) are the 
two dominant incretin hormones and are 
responsible for the so-called “incretin 
effect” (Campbell & Drucker, 2013, p. 
819).  GLP-1 and GIP play an essential 
role in maintaining normal glucose-
homeostasis and in particular 
postprandial glucose levels ("Incretin 
physiology," 2014). Incretin therapy is 
associated with a low risk of adverse 
events such as hypoglycemia (Ahren, 
2013).   
 
GLP-1 
GLP-1 is produced in 
enteroendocrine cells in the distal small 
bowel and colon from L-cells (Drucker, 
2006, p. 153) and binds to a G-protein 
coupled receptor in the endocrine 
pancreas (Burgmaier, Heinrich, & Marx, 
2012). Via stimulation of adenylyl 
cyclase and cyclic adenosine 
monophosphate (cAMP) production 
(Burgmaier et al., 2012, p. 290),  GLP-1 
increases insulin secretion from 
pancreatic β cells and inhibits glucagon 
secretion from α cells, increases insulin 
synthesis, confers glucose sensitivity to 
glucose-resistant β cells, stimulates β 
cell proliferation and regeneration, and 
inhibits β cell apoptosis (Campbell & 
Drucker, 2013).   GLP-1 plasma levels 
rise within minutes after food intake and 
has a short half-life of two minutes and 
like GIP is degraded rapidly by DPP-4 
and excreted via the kidneys (Drucker, 
2013).  GLP-1 lowers blood sugar levels 
and body weight by inhibiting appetite 
by enhancing satiety through its 
hypothalamic action and by slowing 
gastric emptying, which results in a 
decreased influx of glucose into the 
circulation (Pratley, n.d., p. 8).  
 
According to Drucker (2006, p. 154), 
both GLP-1 and GIP stimulate glucose-
dependent insulin secretion via 
activation of their specific G protein-
coupled receptors expressed directly on 
islet β cells. Both hormones stimulate 
insulin gene transcription, increase 
pancreatic β cell mass and protect 
against β cell apoptosis (Vilsboll & Knop, 
2014, p. 2).   
Incretin-based therapies are used as 
add-on therapy to conventional T2DM 
treatment improving glycemic control 
and is generally well tolerated (Capaldi, 
2012). Two classes of incretin-based 
therapies are DPP-4 inhibitors and GLP-
1 receptor agonists. 
DPP-4 is the key enzyme responsible for 
inactivating GIP and GLP-1 and exists in 
two principal forms: a membrane 
anchored, largely extracellular protein 
capable of stimulation of intracellular 
signal transduction pathways 
independent of its enzymatic activity, 
and a circulating soluble enzyme which 
retains enzymatic activity (Drucker, 
2006, p. 160).  According to Drucker 
(2006), genetic evidence supports an 
essential role of DPP-4 in the control of 
glucose homeostasis. 
 DPP-4 inhibitors block the action of 
the enzyme that degrades GLP-1 by 
slowing the rapid degradation of GLP-1 
to the metabolite GLP-1 (9-36) amide 
(Burgmaier et al., 2012, p. 290).  DPP-4 
inhibitors also decrease the degradation 
of other peptides that are substrates to 
DPP-4, including GIP and a variety of 
chemokines (Burgmaier et al., 2012, p. 
290).  According to Capaldi (2012),  
GLP-1 receptor agonists and DPP-4 
inhibitors reduce glucose levels with low 
risk of hypoglycemia and GLP-1 receptor 
agonists are associated with weight loss, 
whereas DPP-4 inhibitors are weight 
neutral (Capaldi, 2012).  DPP-4 
inhibitors are rapidly absorbed and 
excreted by the kidneys; therefore renal 
function should be assessed before their 
use (Aye & Jennings, 2009, p. 197).  
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